This quarterly report represents an earnings surprise of -20%. A quarter ago, it was expected that this specialty pharmaceutical company would post a loss of $0.10 per share when it actually produced a loss of $0.09, delivering a surprise of 10%. Over the last four quarters, the company has surpassed consensus EPS estimates three times. OptiNose, which belongs to the Zacks Medical - Drugs industry, posted revenues of $14.88 million for the quarter ended March 2024, surpassing the Zacks Consensus Estimate by ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ______________. Commission file number: 001-38241 OPTINOSE, INC. (Exact name of registrant as specified in its charter) Delaware 42-1771610 (State ...

Optinose Reports First Quarter 2024 Financial Results and Recent Operational Highlights Company reports Q1 2024 XHANCE net revenue of $14.9 million, an increase of 26% compared to Q1 2023 Company expects peak year XHANCE net revenues of at least $300 million from current specialist focused prescriber audience Company expects to produce positive income from operations (GAAP) for full year 2025 Conference call and webcast to be held today at 10:00 a.m. Eastern Time YARDLEY, Pa., May 14, 2024 Optinose (NASDAQ: ...

YARDLEY, Pa., May 10, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will report financial results for the first quarter 2024 and corporate updates, before market open, on Tuesday, May 14, 2024. Company to Host Conference CallMembers of the Company's leadership team will host a conference call to discuss financial results and corporate updates. The call is scheduled to st ...

YARDLEY, Pa., May 10, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will report financial results for the first quarter 2024 and corporate updates, before market open, on Tuesday, May 14, 2024. Company to Host Conference CallMembers of the Company’s leadership team will host a conference call to discuss financial results and corporate updates. The call is scheduled to st ...

Corporate Presentation March 7, 2024 Forward-looking statements are based upon management's current expectations and assumptions and are subject to a number of risks, uncertainties and other factors that could cause actual results and events to differ materially and adversely from those indicated by such forward-looking statements including, among others: impact of, and the uncertainties caused by, physician and patient acceptance of XHANCE for its current and any potential future indication; our ability to ...

Financial Data and Key Metrics Changes - OptiNose recognized $19.9 million of XHANCE net revenue in Q4 2023, a 5% decrease compared to Q4 2022 net revenues of $20.9 million [12] - For the full year 2023, XHANCE net revenue was $71 million, with an average net revenue per prescription of $209, reflecting a strategic focus on profitability [13][30] - Operating expenses were reduced by $38 million or 31% for the full year 2023 compared to 2022, with significant savings in SG&A [13][29] Business Line Data and Key Metrics Changes - There were approximately 115,000 new prescriptions for XHANCE and 339,000 total prescriptions in 2023, both showing low single-digit percentage decreases compared to 2022 [10] - The average net revenue per prescription increased to $250 in Q4 2023, an 11% increase from $226 in Q4 2022 [30] Market Data and Key Metrics Changes - The company anticipates first quarter 2024 XHANCE net revenues to be approximately $13 million, a 10% increase compared to Q1 2023 [51] - The total addressable market for chronic sinusitis patients is estimated to be between $10 million to $12 million, with one-third of that population cared for in the specialty universe [42] Company Strategy and Development Direction - The company aims to build a profitable ENT and allergy-focused business by leveraging expanded net revenue potential through existing commercial capabilities [6][53] - The supplemental new drug application for XHANCE is under FDA review, with a target action date set for March 16, 2024, which could significantly reshape the business [22][25] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the potential approval of XHANCE as the first prescription treatment for chronic sinusitis, which could increase the patient base significantly [21][22] - The company is focused on optimizing its sales force and distribution strategy to better align with the chronic sinusitis opportunity [9][16] Other Important Information - The company reported a cash position of $73.7 million as of December 31, 2023, indicating a solid financial foundation for future operations [50] - Adjustments to the co-pay assistance program were made to enhance profitability by reducing unprofitable prescriptions [9][30] Q&A Session Summary Question: Can you provide more detail on the sales force and distribution optimization? - The company has realigned its 75 sales territories to focus on the chronic sinusitis opportunity, aiming to reach high-prescribing physicians in that specialty [16][54] Question: What portion of the opportunity can be accessed with existing infrastructure? - The total addressable market for activated patients is estimated at $10 million to $12 million, with about one-third of that population in the specialty universe [42] Question: How has the dialogue with payers been regarding access improvements? - Current contracts with payers are transparent about the pending application for chronic sinusitis, and the company is optimistic about improved access if the label expansion is approved [55]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2023 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from ___________ to ______________. Commission file number: 001-38241 OPTINOSE, INC. (Exact name of registrant as specified in its charter) Delaware 42-1771610 (State of other jur ...

Exhibit 99.1 Optinose Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights PDUFA target action date is March 16, 2024, for the Company's sNDA. If approved, the Company is prepared for launch of XHANCE for treatment of patients diagnosed with chronic sinusitis Physicians diagnose chronic sinusitis 10 times more frequently than XHANCE's current nasal polyps indication and there is no FDA-approved medication for these patients Company reports fourth quarter and full yea ...

‒ Previously expected to be between $64 to $70 million -0.4 | --- | --- | --- | --- | --- | --- | --- | |---------|---------|---------|-------|--------------------------|--------|-----------------| | | | | | | | | | | | | | 0.0 | | | | N = 110 | N = 110 | N = 107 | | -0.2 | N = 75 | N = 72 N = 73 | | | | | | -0.4 | | | | | | | | -0.6 | | | | -0.62 | | | | -0.8 | | | | | | | | -1.0 | -0.81 | | | | | | | CSS Point Reduction -1.2 | | | | | | | | -1.4 | | | | | | | | -1.6 | | -1.54* | | | -1.58‡ | -1.60‡ | | | ...